AbbVie

The Chicago-based biopharmaceutical firm is off to a good start in 2020, having posted another quarter of expectation-beating earnings while enjoying record sales of the world’s best selling drug, Humira. While the growth of biosimilar drugs threatens its Humira franchise in the long term, AbbVie is nurturing other potential blockbusters, including immunology drug Skyrizi. The company also received FDA approval to acquire Botox-maker Allergan, which will provide a booster shot to revenue. AbbVie recently noted the pandemic has reduced prescriptions as a result of a decline in doctor’s office visits, but said it expects this trend to reverse in coming months.